By Dr. Kamal Kant Kohli,Ruchika Sharma

Copyright medicaldialogues

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg. Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism. ZDS- Liothyronine tablets will be manufactured at Zydus’ plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).Read also: Zydus Lifesciences Secures CDSCO Panel Approval for Usnoflast Capsule Interaction StudyZydus Lifesciences Ltd. is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group has a significant presence in cancer related therapies and offers a wide range of solutions with cytotoxic, supportive & targeted drugs. Read also: Zydus Lifesciences Secures CDSCO Panel Approval for Usnoflast Capsule Interaction Study